http://www.fresenius.com en-us Wed, 08 Jul 2020 00:00:00 +0200 Wed, 08 Jul 2020 00:00:00 +0200 Wed, 08 Jul 2020 08:00:00 +0100 <![CDATA[Fresenius holds virtual General Meeting on August 28, 2020 – dividend proposal unchanged ]]> Fresenius will hold its Annual General Meeting (AGM) on August 28, 2020 as a virtual event. Originally, the AGM was scheduled for May 20, 2020. It had to be postponed due to the coronavirus pandemic.

]]>
Wed, 08 Jul 2020 08:00:00 +0100 <![CDATA[Fresenius Helios publishes sustainability report]]> Helios Germany has published its first sustainability report. Oriented to the internationally established standards of the Global Reporting Initiative, this 60-page document outlines the four main target groups and areas that Germany’s largest private hospital operator has defined for its sustainability strategy: Patients, employees, the environment and compliance. Along with numerous statistics and examples from Helios Germany hospitals,  the report sets out the company’s goals for its future development. Titled ”Für eine gesunde Zukunft” (toward a healthy future), the report is now available in German on www.helios-gesundheit.de. An English version will be published soon.

]]>
Tue, 23 Jun 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi expands pre-filled syringe portfolio in the U.S.]]> Morphine Sulfate Injection is now available in the United States in the company’s Simplist™ ready-to-administer prefilled syringes in MicroVault packaging. MicroVault packaging is designed to support the secure dispensing of controlled substances, for example via transparent hard plastic packaging allowing bar code scanning and visual inspection as well as a tamper evident seal.

]]>
Mon, 15 Jun 2020 08:00:00 +0100 <![CDATA[Drug from Fresenius Kabi now available in the U.S. after Emergency Use Authorization]]> Following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization, Fresenius Kabi Propoven 2% is now available in the U.S. Propoven 2% is a higher concentrated dosage form of propofol compared to Fresenius Kabi’s FDA-approved Diprivan® 1%, providing clinicians with another sedation option for ventilated COVID-19 patients. The higher concentration presentation allows Fresenius Kabi to support more patients through more efficient use of existing manufacturing capacity.

]]>
Fri, 29 May 2020 08:00:00 +0100 <![CDATA[Fresenius Helios acquires hospital in western Germany]]> Fresenius Helios is acquiring the Malteser Hospital (“MKHB”) in the western German city of Bonn. The 400-bed acute care hospital, with approximately 750 employees, treats approximately 13,000 patients annually. Its sales last year were about €66 million.

]]>
Thu, 28 May 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi enters marketing agreement for biosimilar product]]> Fresenius Kabi and the pharmaceutical company medac have agreed to cooperate in Germany in the area of treatments for rheumatic illnesses. On June 1, medac’s sales representatives will begin offering the adalimumab biosimilar IDACIO® as an additional therapy option to the rheumatologists and dermatologists they work with. This biosimilar, developed by Fresenius Kabi and launched last year in Europe, is used to treat autoimmune illnesses such as arthritis and psoriasis. medac is a leading provider of methotrexate (metex® PEN, metex® FS) for the parenteral treatment of patients with chronic inflammatory diseases. Since affected patients are often treated with a combination of methotrexate and adalimumab, the partnership between Fresenius Kabi and medac will offer patients and doctors new benefits and synergies in therapy offerings as well as consulting.

]]>
Wed, 27 May 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by FDA]]> Fresenius Kabi announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company`s Biologics License Application (BLA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is an important achievement in the development of Fresenius Kabi’s biosimilar pipeline in the US. Fresenius Kabi also received acceptance for review of its regulatory submission for its pegfilgrastim biosimilar candidate from the European Medicines Agency this month. (* Neulasta® is a registered trademark of Amgen)

]]>
Fri, 22 May 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi’s regulatory submission for pegfilgrastim biosimilar accepted for review by EMA ]]> The European Medicines Agency (EMA) has accepted for review Fresenius Kabi`s Marketing Authorization Application (MAA) for MSB11455, a biosimilar candidate of Neulasta® (pegfilgrastim)*. This is another milestone for Fresenius Kabi following last year`s approval and launch of the company`s adalimumab biosimilar (Idacio®) in Europe. (* Neulasta® is a registered trademark of Amgen)

]]>
Tue, 12 May 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi launches IV Drug in the U.S.]]> Micafungin for injection, an antifungal medicine, expands the company's anti-infective portfolio.

]]>
Thu, 07 May 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi introduces new presentations of Potassium Phosphates Injection ]]> Potassium Phosphates Injection is now available in the United States in three FDA-approved presentations. Fresenius Kabi offers the broadest portfolio of Potassium Phosphates Injection in the United States.

]]>
Wed, 06 May 2020 08:00:00 +0100 <![CDATA[Solid start to 2020 – Fresenius proves its resilience in light of significant COVID-19 effects ]]> Stephan Sturm, CEO of Fresenius, said: “The COVID-19 pandemic has created unprecedented challenges for Fresenius. We are doing everything we can to continue providing the best possible care for our patients around the world. The last few weeks have shown that we have a crucial role to play in the health care systems around the world, and never more so than at a time of crisis.

]]>
Wed, 22 Apr 2020 08:00:00 +0100 <![CDATA[Fresenius Helios develops process for safe reuse of masks]]> Fresenius Helios has developed a secure and highly effective process for purifying medical protective masks so they can be safely reused. It is being employed for FFP2- and FFP3-type masks, which help protect medical and care personnel who are treating COVID-19 patients. Going well beyond the safety standard set out by the Robert Koch Institute, Germany’s government agency responsible for disease control and prevention, the process allows the purified masks to be used by any staff member – not just the previous user. Starting immediately, Helios Germany’s hospitals can purify 8,000 masks daily using the process, which was developed with the support of Fresenius Vamed and Fresenius Medical Care. The company has chosen not to commercialize the process and is making complete information about it available online, free of charge.

]]>
Mon, 20 Apr 2020 08:00:00 +0100 <![CDATA[Fresenius Helios supports COVID-19 research]]> To obtain and secure important data for research into SARS-CoV 2, Fresenius Helios has established a multi-center COVID-19 register. Since back in February a team of Helios experts, supported by the Brandenburg Medical School outside of Berlin, has been gathering pseudonymized data on patients treated for COVID-19 in Germany. The goal is to develop insights and knowledge for the battle against the new virus. First research findings from the project, which is scheduled to last a year and is financed by Helios, are now being readied for publication.

]]>
Tue, 07 Apr 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi takes comprehensive measures to increase supply of essential drugs during COVID 19 pandemic ]]> Production of critical drugs scaled up with priority supply for COVID 19 patients. Commitment to price stability for essential drugs for COVID-19 patients during pandemic.

]]>
Tue, 31 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius successfully places bonds with a volume of 750 million euros]]> Fresenius today successfully places bonds with a volume of €750 million.

]]>
Mon, 30 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius postpones 2020 Annual General Meeting]]> New date will be specified and communicated as soon as reliable planning is possible - Health and safety of shareholders and employees is our priority

]]>
Fri, 27 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius takes comprehensive measures to combat COVID 19 pandemic in Germany]]> Helios Germany is increasing number of intensive care beds by two thirds. Law to ease financial burden on hospitals likely to offset large part of sales losses and cost increases. Digital healthcare offerings facilitate continuous medical care for chronically ill and rehabilitation patients.

]]>
Tue, 24 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius Kabi resumes normal operations in China]]> With virtually all of Fresenius Kabi’s manufacturing staff in China returning to work post government-imposed COVID-19 quarantine restrictions, the company is ramping-up production back to normal levels. With a further stabilization of the situation, Fresenius Kabi also expects a gradual resumption of its sales force activities in China. Even though Fresenius Kabi faced challenges due to the COVID-19 pandemic and the quarantine measures, there was no major interruption of production. Thus, the company can supply the Chinese population with essential pharmaceuticals and medical devices.

]]>
Fri, 20 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius Helios makes significant contribution to combating COVID-19 crisis in Spain]]> All Quirónsalud hospitals are fully operational and managed by Quirónsalud in close coordination with the health authorities. Rumors about a “nationalization” are without any basis.

]]>
Wed, 18 Mar 2020 08:00:00 +0100 <![CDATA[Fresenius subsidiary Curalie acquires Digitale Gesundheitsgruppe]]> Curalie, a subsidiary of Fresenius, has acquired Digitale Gesundheitsgruppe (DGG), one of its main competitors in Germany. Curalie and DGG both develop digital healthcare offerings to help patients with chronic illnesses. DGG targets family and specialist physicians with its “TeLiPro” telemedicine platform, while Curalie develops digital solutions for rehabilitation and aftercare. Combining the two companies creates the first provider that in all sectors of healthcare can digitally support patients during outpatient and inpatient care and through to aftercare.

]]>